selonsertib
Small moleculeexperimental
Clinical trial activity
10 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
9
Phase 3
3
Phase 4
0
Earliest trial started Jun 1, 2014 (NCT02177786)
Timeline
Indications
Mechanism of action
MAP3K5 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1cc(F)c(C(=O)Nc2cccc(-c3nncn3C(C)C)n2)cc1-n1cnc(C2CC2)c1- Mol. weight
- 445.5 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3916717 ↗
- ChEMBLCHEMBL3545429 ↗
Also known as
- gs-4997
- gs-4997
- gs-4997
- selonsertib
- selonsertib
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04026165 | Phase 3 | Aug 31, 2019 | Gilead Sciences |
| NCT03449446 | Phase 2 | Mar 21, 2018 | Gilead Sciences |
| NCT03053050 | Phase 3 | Feb 13, 2017 | Gilead Sciences |
| NCT03053063 | Phase 3 | Jan 30, 2017 | Gilead Sciences |
| NCT02854631 | Phase 2 | Aug 31, 2016 | Gilead Sciences |
| NCT02781584 | Phase 2 | Jul 13, 2016 | Gilead Sciences |
| NCT02509624 | Phase 1 | Aug 1, 2015 | Gilead Sciences |
| NCT02466516 | Phase 2 | Jun 1, 2015 | Gilead Sciences |
| NCT02234141 | Phase 2 | Nov 1, 2014 | Gilead Sciences |
| NCT02177786 | Phase 2 | Jun 1, 2014 | Gilead Sciences |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Gilead Sciences | For profit | 10 | 10 | 3 | 2014 |
1 organizations
Page 1 / 1